Mag. Dr. Alexander Pretsch, BSc.

Chief Executive Officer

Alexander is an experienced biotech founder and CEO (SeaLife Pharma, Marinomed, Endochilabs) with a successful industrial track record. He holds a degree in biomedicine, biology and biotechnology with focus on infection diseases and drug development and is a leading expert for medicinal chemistry and compound optimization. He has more than 20 years of experience in academic and industrial settings with development expertise in the pharmaceutical and med.-tech. area. Alexander is member of several international Advisory Boards, was Executive Board member in Pharmasea, an international discovery program, and is teaching drug discovery and development at national and international universities for more than ten years.

DI. Dr. Miroslav Genov

Chief Scientific Officer

Miroslav has an excellent track record of leading the chemical synthesis and medicinal chemistry programs for various drug development programs and has more than 20 years of experience working in industrial and academic settings. Miroslav holds a PhD in Chemistry from the Institute of Organic Chemistry with Centre of Phytochemistry at the Bulgarian Academy of Sciences (with Prof. V. Dimitrov). Before joining the Department of Inorganic Chemistry at the University of Valladolid, Spain as Assistant Professor, Miroslav trained as Research Fellow with Professor Andreas Pfaltz at the University of Basel, Switzerland and at the Max Plank Institute for Coal Research, Mülheim an der Ruhr, Germany.

Dr. MSc. Dagmar Pretsch, BSc.

Chief Technical Officer

Dagmar is a leading expert in C. elegans drug screening platforms and is responsible for the optimization and expansion of the Oxford Antibiotic Group’s screening platforms. Dagmar has over ten years of experience in drug screens using antibacterial, antiviral and cellular assays. In her previous roles in biotech and pharma, Dagmar was involved in a number of drug development programs in antibiotics, and neurological disorders. Dagmar holds a PhD in pharmacy, a MSc. in Neurobiology and a BSc. in biomedicine and biotechnology from the University of Vienna and worked at the Department of Pharmacognosy at the University of Vienna before joining Oxford Antibiotics Group. For her PhD thesis, Dagmar was awarded a prestigious Doc-fellowship from the Austrian Academy of Sciences.

Dr. Walter Welz

Head of Chemical Analytics

Walter holds a PhD in biochemistry and has more than 30 years’ experience in chemical analytics. He holds several leading positions in hospitals, universities and companies with the focus of analytical examination of natural products and final drugs. He worked for Sanofi as head of analytics in their last antibiotic development program until 2019. Walter is an expert for international authorization documents, compilation of expert’s reports for the chemical pharmaceutical part of registration documents, implementation of GLP and method development. He is a Qualified Person at the Austrian Ministry of Health and member of national and international chemical societies.